Test Code HCCGS Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum
Ordering Guidance
GALAD model (gender, age, alpha-fetoprotein [AFP]-L3, AFP, des-gamma-carboxy prothrombin [DCP]) score testing (this test) should not be performed for patients who are pregnant, as alpha-fetoprotein results are elevated during pregnancy.
Necessary Information
Sex and age are required.
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL Serum
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Risk assessment for development of hepatocellular carcinoma in patients with chronic liver disease
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| L3AFP | AFP-L3% and Total AFP, S | Yes | Yes |
| DCP | Des-Gamma-Carboxy Prothrombin, S | Yes | Yes |
| GAL1 | GALAD Model Score | No | Yes |
Method Name
L3AFP, DCP: Isotachophoresis with Laser-Induced Fluorescence
GAL1: Calculation
Reporting Name
HCC Risk Panel with GALAD Score, SSpecimen Type
SerumSpecimen Minimum Volume
Serum: 0.25 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Frozen (preferred) | 90 days |
| Refrigerated | 5 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Gross icterus | OK |
Clinical Information
Worldwide, hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death.(1) HCC can be treated effectively in its early stages, but most patients are not diagnosed until they are symptomatic and the disease is at a higher grade and stage, which are less responsive to therapy. Alpha-fetoprotein (AFP) is the standard serum tumor marker utilized in the evaluation of suspected HCC. However, serum AFP concentrations may also be increased in chronic hepatitis, liver cirrhosis, and other tumor types (eg, germ cell tumors),(2) which decreases the specificity of AFP testing for HCC. Furthermore, AFP is not expressed at high levels in all HCC patients, resulting in decreased sensitivity, especially for small tumors that are potentially curable.
AFP-L3:
Alpha-fetoprotein is differentially glycosylated in several hepatic diseases. For example, alpha-(1,6)-fucosyltransferase is differentially expressed in hepatocytes following malignant transformation.(3) This enzyme incorporates fucose residues to the carbohydrate chains of AFP. After electrophoresis, different glycosylated forms of AFP can be identified by their reaction with different carbohydrate-binding plant lectins. The fucosylated form of serum AFP most closely associated with HCC reacts with a lectin from the common lentil (Lens culinaris). This form is designated as AFP-L3 (third electrophoretic form of lentil lectin-reactive AFP). AFP-L3 is most useful for differential diagnosis in patients with a total serum AFP of 200 ng/mL or less, which can result from a variety of benign conditions, such as chronic liver disease.
Des-gamma-carboxy prothrombin:
Des-gamma-carboxy prothrombin (DCP), also known as the protein induced by vitamin K absence or antagonist II (PIVKA-II), is an abnormal, nonfunctional form of the coagulation protein prothrombin. DCP results from a lack of carboxylation of 10 glutamic acid residues in the N-terminal portion of the molecule. In normal liver, prothrombin undergoes post-translational carboxylation before release into the peripheral blood. Carboxylation converts specific amino-terminal glutamic acid residues to gamma-carboxyglutamic acid. Many HCC cells lack the vitamin K-dependent carboxylase responsible for carboxylation, so they secrete an abnormal prothrombin in which some or all glutamic acid residues remain unconverted. This noncarboxylated form (DCP) is therefore used as an HCC biomarker.
Des-gamma-carboxy prothrombin is a complementary biomarker to AFP and AFP-L3 for assessing the HCC risk. Elevations of both AFP-L3 and DCP indicate HCC progression, although they reflect different features of progression. In a prospective study of patients in the United States with an established diagnosis of HCC, the sensitivities for AFP, AFP-L3, and DCP were 68%, 62%, and 73%, respectively. When the 3 markers were combined, the sensitivity was 86%. In another study, DCP levels correlated with tumor size and metastatic HCC. In that study, compared to AFP and AFP-L3, DCP had the highest sensitivity (87%) and the highest positive predictive value (87%) in patients with HCC due to chronic hepatitis B and C infections. A number of studies have shown that elevated serum DCP is significantly related to portal vein invasion and intrahepatic metastasis, both of which significantly affect prognosis in patients with HCC.
Des-gamma-carboxy prothrombin can also be elevated in conditions other than HCC. Obstructive jaundice, intrahepatic cholestasis that chronically decreases vitamin K, and ingestion of drugs such as warfarin or broad-spectrum antibiotics can cause high DCP concentrations. In addition, 25% to 50% of patients with HCC will have a DCP value within the normal reference interval. A normal DCP value therefore does not rule out HCC.
Gender, Age, AFP-L3, AFP, DCP (GALAD) Score:
Hepatocellular carcinoma biomarkers include AFP, AFP-L3, and DCP. The GALAD model combines these 3 biomarkers with the patient's sex and age to estimate the HCC risk in patients with chronic liver disease based on the following equation:
Z = -10.08 + 0.09 x age + 1.67 x sex + 2.34 log(10) (AFP) + 0.04 x AFP - L3 + 1.33 x log(10) (DCP), where sex = 1 for males, 0 for females.
When %AFP-L3, Total AFP, or DCP is below the lower limit of quantitation (LLOQ), the GALAD score is calculated using the LLOQ and reported as <GALAD score.
The GALAD model detects HCC more accurately than when AFP, AFP-L3, and DCP markers are used alone or in combination. The performance of the GALAD score has also been reported to be superior to ultrasound for HCC detection.
Reference Values
TOTAL ALPHA-FETOPROTEIN (AFP):
<4.7 ng/mL
AFP L3-PERCENT:
<10%
DES-GAMMA-CARBOXY PROTHROMBIN:
<7.5 ng/mL
GAL1:
Not applicable
Interpretation
Alpha-fetoprotein (AFP)-L3 results of 10% or more are associated with a 7-fold increased risk of developing hepatocellular carcinoma (HCC). Patients with AFP-L3 levels of 10% or more should be closely monitored for evidence of hepatocellular carcinoma according to current practice guidelines.
Total serum AFP results above 200 ng/mL are highly suggestive of a diagnosis of HCC. In patients with liver disease, a total serum AFP level above 200 ng/mL is near 100% predictive of HCC. With lower total AFP levels, there is an increased likelihood that chronic liver disease, rather than HCC, is responsible for the AFP elevation.
Based on a retrospective study at Mayo Clinic, for patients with total AFP levels of 200 ng/mL or less, AFP-L3 specificity approaches 100% for HCC when its percentage exceeds 35% of the total AFP.(4)
Alpha-fetoprotein concentrations over 100,000 ng/mL have been reported in normal newborns, and the values rapidly decline in the first 6 years of life.
Des-gamma-carboxy prothrombin:
In patients with an elevated des-gamma-carboxy prothrombin (DCP) result (≥7.5 ng/mL), the risk of developing HCC is 36.5% (95% CI 23.5%-49.6%). The risk of developing HCC with a negative DCP result (<7.5 ng/mL) is 7.6% (95% CI 4.4%-10.8%).
Gender, Age, AFP-L3, AFP, DCP (GALAD) Score:
Higher GALAD model scores correlate with increased risk of HCC. The area under the curve (AUC) of a receiver operating characteristic curve of the GALAD score was 0.95 for all HCC detection, and 0.92 for the detection of early-stage HCC. Additionally, the AUC of the GALAD score (0.95) was higher than that of ultrasound alone for all HCC detection (AUC of 0.82, P <0.01).
The sensitivity and specificity performance characteristics of the GALAD score for HCC will be influenced by the selected GALAD score cut-off. For example, at an optimal AUC cutoff of -0.76, the GALAD score had 91% sensitivity and 85% specificity for HCC detection. At a more specific GALAD score cutoff of 0.88, the observed sensitivity was 80% for HCC detection with an observed specificity of 97%.
The GALAD model was developed and validated in patient cohorts with a prevalence of HCC ranging from 35% to 49%. The performance of the model may be altered in populations with different HCC prevalence. In addition, the clinical performance of the GALAD score varies by etiology of HCC and therefore may be different in different regions of the world.
Cautions
Serum markers are not specific for malignancy, and values may vary by method. Do not interpret alpha-fetoprotein (AFP), AFP-L3, and des-gamma-carboxy prothrombin (DCP) levels as absolute evidence of the presence or absence of malignant disease. Results should be used in conjunction with information from the clinical evaluation of the patient, cytology, and imaging procedures.
Values obtained with different assay methods or kits cannot be used interchangeably.
In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation.
Test results for AFP are not interpretable if the patient is pregnant.
Des-gamma-carboxy prothrombin-producing tumors other than hepatocellular carcinoma can show elevated DCP values. Liver disease caused by other etiologies, such as alcohol-induced liver disease, hemochromatosis, Wilson disease, autoimmune hepatitis, and steatohepatitis have not been studied with the DCP assay.
Medications containing vitamin K may cause a negative bias with DCP values. Medications containing vitamin K antagonist or antibiotic may cause a positive bias with DCP values.
The total AFP and AFP-L3 test values must be obtained using the uTASWako i30 in the GALAD (gender, age, AFP-L3, AFP, des-gamma-carboxy prothrombin) score calculation.
Method Description
Testing is performed using the uTASWako i30 instrument and the test system reagents.
Alpha-fetoprotein L3:
Total alpha-fetoprotein (AFP) is measured by laser-induced fluorescence with separation of the lentil lectin-reactive AFP-L3 and lectin nonreactive forms of AFP by isotachophoresis of their immune-complexes. Results are expressed as the percent ratio of AFP-L3 to total AFP.(Package insert: uTASWako i30 AFP-L3. Wako Diagnostics; 04/2026)
Des-gamma-carboxy prothrombin:
Sample is added to the reagent well with the fluorescent dye labeled antihuman prothrombin antibody (mouse monoclonal) to form the primary immunocomplex. The second labeled antibody solution, anion-conjugated antihuman des-gamma-carboxy prothrombin (DCP) antibody (mouse monoclonal), is concentrated by isotachophoresis when voltage is applied. The concentrated anion-conjugated antibody then reacts with the primary immunocomplex to form the secondary immunocomplex. This secondary complex is further concentrated during isotachophoresis and is separated from unbound fluorescent dye-labeled antibody by capillary gel electrophoresis. The remaining dye labeled DCP is measured by laser-induced fluorescence. The concentration of DCP in the specimen is directly proportional to the amount of fluorescence.(Package insert: uTASWako i30 DCP. Wako Diagnostics; 04/2026)
Gender, age, AFP-L3, AFP, DCP, and (GALAD) model score:
The GALAD model is a statistical model for estimating the likelihood of hepatocellular carcinoma in patients with chronic liver disease. The GALAD score is calculated based on gender, age, and measured concentrations of AFP-L3, AFP and DCP.
Day(s) Performed
Monday through Friday
Report Available
1 to 4 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82107
83951
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| HCCGS | HCC Risk Panel with GALAD Score, S | 96452-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| TAFP | Total AFP, S | 1834-1 |
| DCP | Des-Gamma-Carboxy Prothrombin, S | 34444-0 |
| GAL1 | GALAD Model Score | 96450-2 |
| L3 | %L3 | 42332-7 |
| INT67 | Interpretation | 69048-7 |